{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:52:58Z","timestamp":1791301978159,"version":"4.1.0"},"reference-count":53,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Annals of Neurology"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>Master protocol trials allow for simultaneous multiple hypothesis testing within a common framework and might be applicable for rare diseases. In May 2025, the Network for Excellence in Neuroscience Clinical Trials convened a multistakeholder conference to discuss master protocol trials in rare neurological disorders. In this paper, we explore how master protocol trial designs may apply to rare neurological disorders, using the neuronal ceroid lipofuscinoses as an example. Through shared protocol elements and trial infrastructure, master protocols may decrease cost and improve efficiency in testing potential therapeutics in rare disease, accelerating the delivery of urgently needed therapies to patients. ANN NEUROL 2026;100:477\u2013486<\/jats:p>","DOI":"10.1002\/ana.78311","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T12:08:11Z","timestamp":1784635691000},"page":"477-486","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Case for Master Protocols for Rare Neurological Diseases"],"prefix":"10.1002","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3893-2922","authenticated-orcid":false,"given":"Jennifer","family":"Vermilion","sequence":"first","affiliation":[{"name":"Department of Neurology University of Rochester Medical Center  Rochester New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Paganoni","sequence":"additional","affiliation":[{"name":"Sean M. Healey &amp; AMG Center for ALS and Neurological Clinical Research Institute Massachusetts General Hospital, Harvard Medical School  Boston Massachusetts USA"},{"name":"Spaulding Rehabilitation Hospital  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R.","family":"Plotkin","sequence":"additional","affiliation":[{"name":"Department of Neurology and Cancer Institute; Mass General Brigham Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Quintana","sequence":"additional","affiliation":[{"name":"Berry Consultants  Austin Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4229-2729","authenticated-orcid":false,"given":"Sara B.","family":"Calvert","sequence":"additional","affiliation":[{"name":"Clinical Trials Transformation Initiative Duke University  Durham North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ineka T.","family":"Whiteman","sequence":"additional","affiliation":[{"name":"Batten Disease Support Research and Advocacy Foundation  Columbus Ohio USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond Y.","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Metabolic Disorders Rady Children's Health  Orange California USA"},{"name":"Department of Pediatrics University of California\u2010Irvine School of Medicine  Orange California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Moore","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit Kennedy Krieger Institute  Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7257-8985","authenticated-orcid":false,"given":"Erika F.","family":"Augustine","sequence":"additional","affiliation":[{"name":"Clinical Trials Unit Kennedy Krieger Institute, Department of Neurology, Johns Hopkins Medicine  Baltimore Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"e_1_2_13_2_1","unstructured":"Biological Approvals by Year Available at:https:\/\/www.fda.gov\/vaccines-blood-biologics\/development-approval-process-cber\/biological-approvals-year."},{"key":"e_1_2_13_3_1","unstructured":"Novel Drug Approvals at FDA Available at:https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/novel-drug-approvals-fda. Accessed July 29 2025."},{"key":"e_1_2_13_4_1","unstructured":"Orphan Drug Act1983."},{"key":"e_1_2_13_5_1","unstructured":"Rare Diseases Act of 2002 2002."},{"key":"e_1_2_13_6_1","unstructured":"MedlinePlus: Nervous System Diseases Available at:https:\/\/medlineplus.gov\/neurologicdiseases.html."},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-019-00180-y"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-019-03778-7"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-019-03764-z"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.11122"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2024.100263"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw413"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06388-8"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/0883073813495959"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.c.32031"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-024-00020-8"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03191-1"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3664-1"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.0367"},{"key":"e_1_2_13_20_1","unstructured":"U.S. Food and Drug Administration (FDA).Master Protocols for Drug and Biological Product Development Guidance for Industry. Notice of Availability in the Federal Register on December 22 2023."},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510062"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.05.010"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2015.07.009"},{"key":"e_1_2_13_24_1","unstructured":"Medicine M\u2010NIoG.OMIM Pace of Gene Discovery Graph Available at:https:\/\/www.omim.org\/statistics\/paceGraph."},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.21140"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-04048-w"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-023-07398-7"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032200"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26285"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.28442"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26714"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.59058"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.5249"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.26429"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.27643"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00173-5"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0325826"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-024-00740-x"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-3278"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197350"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400985"},{"key":"e_1_2_13_42_1","unstructured":"Clinical Trials Transformation Initiative (CTTI).Master Protocol Design & Implementation: Charting Multi\u2010Stakeholder Pathways to Success 2021. Available at:https:\/\/ctti-clinicaltrials.org\/wp-content\/uploads\/2021\/2006\/CTTI_Master_Protocol_Roadmap.pdf."},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1177\/17407745221110199"},{"key":"e_1_2_13_44_1","unstructured":"U.S. Food and Drug Administration (FDA).Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics: Guidance for Industry [Draft Guidance] 2023."},{"key":"e_1_2_13_45_1","unstructured":"U.S. Food and Drug Administration (FDA).Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products Guidance for Industry [Draft Guidance] 2023."},{"key":"e_1_2_13_46_1","unstructured":"Clinical Trials Transformation Initiative (CTTI).Master Protocol FDA Engagement Tool 2021. Available at:https:\/\/ctti-clinicaltrials.org\/wp-content\/uploads\/2021\/2006\/CTTI_Master_Protocol_FDA_Engagement_Tool.pdf."},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/0883073813494268"},{"key":"e_1_2_13_48_1","unstructured":"Batten Disease Support Research and Advocacy (BDSRA) Foundation.Clinical Trials & Natural History Studies Available at:https:\/\/bdsrafoundation.org\/research\/clinical-studies\/."},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0931-2"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-022-00448-3"},{"key":"e_1_2_13_51_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-020-05009-3"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10717-0"},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201660"},{"key":"e_1_2_13_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2025.10.006"}],"container-title":["Annals of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ana.78311","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ana.78311","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ana.78311","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:00:25Z","timestamp":1791298825000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.78311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1002\/ana.78311"],"URL":"https:\/\/doi.org\/10.1002\/ana.78311","archive":["Portico"],"relation":{},"ISSN":["0364-5134","1531-8249"],"issn-type":[{"value":"0364-5134","type":"print"},{"value":"1531-8249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"2026-04-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}